Reham Abdelkader | Pharmacology | Best Researcher Award

Published on by Health Scientists

Prof. Reham Abdelkader | Pharmacology | Best Researcher Award 

Head of department | German university in Cairo | Egypt

Dr. Reham Mahmoud Abdel-Kader, Professor of Pharmacology and Toxicology and Chair of the Department at the German University in Cairo, is a distinguished biomedical scientist whose research bridges molecular pharmacology, neurodegenerative diseases, and cancer biology with translational therapeutic innovation. Her scientific contributions focus on elucidating mitochondrial dysfunction, neuroinflammation, and cellular bioenergetics as critical mechanisms in Alzheimer’s disease and oncological disorders, advancing targeted treatment approaches through nanotechnology and pharmacogenomic insights. Dr. Abdel-Kader has established two active research groups investigating Alzheimer’s pathology and mitochondrial roles in breast cancer progression, fostering a strong translational link between bench discovery and therapeutic development. She has published widely in internationally recognized journals in pharmacology, neurobiology, and molecular medicine, and her work has received global recognition through prestigious conference presentations and features in leading scientific outlets. Her research has attracted significant international funding from agencies such as the Swiss National Science Foundation, DAAD-BMBF, and the Science and Technology Development Fund, reflecting the impact and sustainability of her scientific endeavors. A committed academic leader, she has played a vital role in curriculum development, accreditation processes, and capacity-building initiatives that enhance educational quality and research excellence within her institution. Dr. Abdel-Kader actively collaborates with leading scientists and institutions across Europe, including partnerships in Germany and Switzerland, fostering international scientific exchange and innovation. Her patent in nanocomposite synthesis further underscores her commitment to bridging pharmaceutical research and technology-based solutions. Through her scholarly rigor, mentorship, and collaborative leadership, Dr. Abdel-Kader continues to contribute significantly to global pharmacological sciences and to shaping the next generation of health researchers dedicated to advancing human health and societal well-being.

Profiles: Google Scholar | ORCID

Featured Publications

1. Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., & others. (2007). Mitochondrial dysfunction: The first domino in brain aging and Alzheimer’s disease? Antioxidants & Redox Signaling,

2. Abdel-Kader, R., Hauptmann, S., Keil, U., Scherping, I., Leuner, K., Eckert, A., & others. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research,

3. Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., & others. (2012). Mitochondrial dysfunction—A pharmacological target in Alzheimer’s disease. Molecular Neurobiology,

4. Franke, C., Nöldner, M., Abdel-Kader, R., Johnson-Anuna, L. N., Wood, W. G., & others. (2007). Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiology of Disease

5. Eckert, G. P., Schiborr, C., Hagl, S., Abdel-Kader, R., Müller, W. E., & Rimbach, G. (2013). Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochemistry International.

Siyu Chen | Pharmacology | Best Researcher Award

Published on by Health Scientists

 Prof. Siyu Chen | Pharmacology | Best Researcher Award

Professor | China Pharmaceutical University | China

Dr. Chen Siyu currently serves as the Deputy Director of the Department of Biochemistry at the School of Life Sciences and Technology, China Pharmaceutical University, where he is also a Professor, Doctoral Supervisor, and Chief Young Scientist of the National Key Research and Development Program. He obtained his academic training in biochemistry and molecular biology, cultivating a strong foundation in metabolic and biochemical sciences. Dr. Chen’s research primarily focuses on Target Discovery and Intervention Strategies for Metabolic Diseases, aiming to elucidate molecular mechanisms and identify novel therapeutic targets for metabolic regulation. He has published extensively as first or corresponding author in leading international journals such as Advanced Science, Nature Communications, and Gut Microbes, with his work widely cited by peers. His innovative research has led to the granting of national patents and multiple ongoing patent applications. Dr. Chen has successfully led major research projects under national and provincial funding programs, including the National Key R&D Program for Young Scientists, the National Natural Science Foundation for Young Scientists, and the Jiangsu Province Excellent Youth Fund. Recognized for his scholarly excellence, he received the Outstanding Doctoral Dissertation Award of Jiangsu Province. In addition to his research, Dr. Chen contributes actively to the academic community as a Young Member of the Metabolism Committee of the Chinese Society of Biochemistry, Director of the Jiangsu Society of Developmental Biology, and Editorial Board Member of Journal of China Pharmaceutical University and Progress in Biochemistry and Biophysics. He also serves as a Guest Editor for Frontiers in Endocrinology and a regular reviewer for leading journals including Journal of Hepatology and ACS Nano. He has 1616 citations from 60 documents with an h-index of 24.

Profiles: Scopus | ORCID

Featured Publications

1. Photosensitive biomimetic nanomedicine-mediated recombination of adipose microenvironments for antiobesity therapy. (2025). Advanced Materials.

2. Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity. (2025). Bioengineering and Translational Medicine.

3. Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex. (2024). Cell Communication and Signaling.

4. Luteolin detoxifies DEHP and prevents liver injury by degrading Uroc1 protein in mice. (2024). EMBO Molecular Medicine.

5. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. (2024). Phytomedicine.

Amin Hasanvand | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Amin Hasanvand | Pharmacology | Best Researcher Award

Associate Professor | Lorestan University | Iran

Dr. Amin Hasanvand, Associate Professor in the Department of Pharmacology at Lorestan University of Medical Sciences, is an accomplished Iranian pharmacologist and biomedical scientist whose career reflects excellence in research, teaching, and leadership in health sciences. He earned his Ph.D. in pharmacology from Tehran University of Medical Sciences in 2016, with a doctoral thesis focused on the AMPK signaling pathway and its role in diabetic neuropathy, and has since developed a robust academic profile. His research interests span pharmacology, diabetes, nephropharmacology, inflammation, neuropathy, and neuroscience, with particular focus on AMPK-dependent mechanisms, metformin, gut microbiome modulation, and novel strategies for neuropathic pain management. Over the years, Dr. Hasanvand has published more than 50 peer-reviewed articles in SCI and Scopus-indexed journals, authored two academic books titled Medical Pharmacology Education and Antibiotics: Mechanisms of Action and Clinical Applications, and contributed to over 40 completed research projects, while actively mentoring medical and pharmacy students. He also serves as Editor of the Herbal Medicine Journal and as an editorial board member of Annals of Pharmacology and Immunopathologia Persa, alongside being a reviewer for leading international journals such as Journal of Neuroimmune Pharmacology, Cancer Control, and Obesity Reviews. In recognition of his impactful contributions, Dr. Hasanvand has been honored seven times as the top researcher at his university and was ranked among the world’s top 2% most influential scientists in 2023. His distinguished career reflects an enduring commitment to advancing pharmacological sciences and improving health outcomes through research, innovation, and education. He has 809 citations from 38 documents with an h-index of 14.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Mir, S., Abbaszadeh, A., Hasanpour Dehkordi, A., & Hasanvand, A. (2019). Metformin and its anti-inflammatory and anti-oxidative effects; new concepts. Journal of Renal Injury Prevention.

2. Hasanvand, A., Kharazmkia, A., Mir, S., Khorramabadi, R. M., & Darabi, S. (2018). Ameliorative effect of ferulic acid on gentamicin-induced nephrotoxicity in a rat model; role of antioxidant effects. Journal of Renal Injury Prevention.

3. Khorramabadi, R. M., Amanolahi Baharvand, P., Pirzadroozbahani, N., Hasanvand, A., Kharazmkia, A., Goudarzi, M., Mir, S., & Ahmadizar, F. (2018). Evaluation of the antioxidant effects of zolpidem in the rat model of cisplatin-induced nephrotoxicity. Journal of Renal Injury Prevention.

4. Hasanvand, A., Amini-Khoei, H., Jahanabadi, S., Hadian, M.-R., Abdollahi, A., Tavangar, S. M., Mehr, S. E., & Dehpour, A. R. (2018). Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through activation of AMPK signaling pathway. Journal of Nephropathology.

5. Abbaszadeh, A., Koushki, S., Koushki, S., Eskandarzadeh, M., & Hasanvand, A. (2018). Metformin; a mini-review to its antioxidative and anti-inflammatory properties. Journal of Renal Injury Prevention.

6. Babaeenezhad, E., & Hasanvand, A. (2018). Renoprotective impacts of metformin with insulin in type 1 diabetes; role of its antioxidant efficacy. Journal of Nephropathology.